SRTS (Sensus Healthcare) Current Deferred Revenue: $0.64 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRTS Sensus Healthcare Inc SRTS
74 GF Score
Price $2.89
GF Value $2.71
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Sensus Healthcare Current Deferred Revenue?

Sensus Healthcare SRTS -2.26% 74 Current Deferred Revenue is $0.64 Mil as of Mar. 2026. GuruFocus rates SRTS with a GF Score™ of 74/100 and a GF Value™ of $2.71 (Fairly Valued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Sensus Healthcare's current deferred revenue for the quarter that ended in Mar. 2026 was $0.64 Mil.

Sensus Healthcare Current Deferred Revenue Related Terms

Sensus Healthcare Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Sensus Healthcare's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensus Healthcare Current Deferred Revenue Chart

Sensus Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.17 0.69 0.66 0.54 0.84

Sensus Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.53 0.65 0.84 0.64
SRTS
74GF Score
Sensus Healthcare Inc SRTS
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.64 Mil mean?
Sensus Healthcare (SRTS) has a Current Deferred Revenue of $0.64 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sensus Healthcare and its competitors.
Is Sensus Healthcare's Current Deferred Revenue too high?
Sensus Healthcare's current Current Deferred Revenue is $0.64 Mil. Overall, Sensus Healthcare has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sensus Healthcare's Current Deferred Revenue compare to SNWV and COCH?
Sensus Healthcare's Current Deferred Revenue of $0.64 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sensus Healthcare and its competitors. Sensus Healthcare's current Current Deferred Revenue is $0.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensus Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sensus Healthcare (SRTS) is currently considered Fairly Valued. The stock's GF Value™ is $2.71, compared to a current price of $2.89 — trading 6.8% above its estimated fair value. The current Current Deferred Revenue is $0.64 Mil. Sensus Healthcare's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Sensus Healthcare (SRTS), the current Current Deferred Revenue is $0.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sensus Healthcare (SRTS) Overvalued in 2026?

Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued. The current stock price of $2.89 is trading 6.8% above its estimated GF Value™ of $2.71. GuruFocus considers Sensus Healthcare to be Fairly Valued.

Key valuation signals for SRTS:

  • Current Deferred Revenue: $0.64 Mil
  • GF Value™: $2.71 vs. price of $2.89 (6.8% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sensus Healthcare Business Description

Other Exchanges 5TX:Germany
Address 851 Broken Sound Parkway, NW, Suite 215, Boca Raton, FL, USA, 33487
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
74GF Score

Get the complete analysis for SRTS

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.89
Price
$2.71
GF Value